Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Maspero

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
The World Allergy Organization Journal|March 11, 2024
Management of CRSwNP in Latin America: A multidisciplinary consensus from an expert working groupJorge F Maspero, Wilma Anselmo-Lima, David Bedoya, et al.
Eclinicalmedicine|May 17, 2021
Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)Mario Castro, Edward Kerwin, David Miller, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 19, 2011
Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North AmericaC H Katelaris, B W Lee, P C Potter, et al.
The Lancet. Respiratory Medicine|March 5, 2015
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsMario Castro, James Zangrilli, Michael E Wechsler, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|February 7, 2013
Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled studyPaul Potter, Jorge F Maspero, Jan Vermeulen, et al.
The World Allergy Organization Journal|November 5, 2013
Insights, attitudes, and perceptions about asthma and its treatment: findings from a multinational survey of patients from Latin AmericaJorge F Maspero, Jose R Jardim, Alvaro Aranda, et al.
Journal of Asthma and Allergy|April 7, 2023
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 StudiesJorge F Maspero, Claus Bachert, Fernando J Martinez, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 28, 2015
Taking Aim at Asthma Around the World: Global Results of the Asthma Insight and Management Survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United StatesRobert A Nathan, Philip J Thompson, David Price, et al.
Respiratory Medicine|March 11, 2023
Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM studyRichard N Van Zyl-Smit, Huib Am Kerstjens, Jorge F Maspero, et al.
The Lancet. Respiratory Medicine|April 5, 2026
Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 studyJorge F Maspero, Ian D Pavord, Michael E Wechsler, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
The World Allergy Organization Journal|March 11, 2024
Management of CRSwNP in Latin America: A multidisciplinary consensus from an expert working groupJorge F Maspero, Wilma Anselmo-Lima, David Bedoya, et al.
Eclinicalmedicine|May 17, 2021
Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)Mario Castro, Edward Kerwin, David Miller, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 19, 2011
Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North AmericaC H Katelaris, B W Lee, P C Potter, et al.
The Lancet. Respiratory Medicine|March 5, 2015
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsMario Castro, James Zangrilli, Michael E Wechsler, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|February 7, 2013
Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled studyPaul Potter, Jorge F Maspero, Jan Vermeulen, et al.
The World Allergy Organization Journal|November 5, 2013
Insights, attitudes, and perceptions about asthma and its treatment: findings from a multinational survey of patients from Latin AmericaJorge F Maspero, Jose R Jardim, Alvaro Aranda, et al.
Journal of Asthma and Allergy|April 7, 2023
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 StudiesJorge F Maspero, Claus Bachert, Fernando J Martinez, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 28, 2015
Taking Aim at Asthma Around the World: Global Results of the Asthma Insight and Management Survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United StatesRobert A Nathan, Philip J Thompson, David Price, et al.
Respiratory Medicine|March 11, 2023
Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM studyRichard N Van Zyl-Smit, Huib Am Kerstjens, Jorge F Maspero, et al.
The Lancet. Respiratory Medicine|April 5, 2026
Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 studyJorge F Maspero, Ian D Pavord, Michael E Wechsler, et al.
Pageof 6